Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.~* Castration-resistant prostate cancer (CRPC) with castrate level of serum testosterone.~* Prostate-specific Antigen (PSA) doubling time of ≤ 10 months and PSA \> 2ng/ml.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~* Blood counts at screening: haemoglobin ≥ 9.0 g/dl,absolute neutrophil count ≥ 1500/µl, platelet count ≥ 100,000/µl.~* Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) ≤ 2.5 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN, creatinine ≤ 2.0 x ULN.~* Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method and refrain from sperm donation during the study treatment and for 3 months after the end of the study treatment.~Exclusion Criteria:~* History of metastatic disease at any time or presence of detectable metastases.~* Acute toxicities of prior treatments and procedures not resolved to grade ≤ 1 or baseline before randomisation.~* Prior treatment with: second generation androgen receptor (AR) inhibitors, other investigational AR inhibitors, or CYP17 enzyme inhibitor.~* Use of estrogens or 5-α reductase inhibitors or AR inhibitors.~* Prior chemotherapy or immunotherapy for prostate cancer.~* Use of systemic corticosteroid.~* Radiation therapy within 12 weeks before randomisation.~* Severe or uncontrolled concurrent disease, infection or co-morbidity.~* Treatment with bisphosphonate or denosumab within 12 weeks before randomisation.~* Known hypersensitivity to the study treatment or any of its ingredients.~* Major surgery within 28 days before randomisation.~* Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV.~* Uncontrolled hypertension.~* Prior malignancy.~* Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.~* Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.~* Treatment with any investigational drug within 28 days before randomisation.~* Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darolutamide (BAY1841788) (Type: EXPERIMENTAL): Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo 2 tablets twice daily with food.

Based on this trial design, predict the completion outcome and termination type (if applicable).